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Abstract 
Background: To examine the effects of the DPP-4i sitagliptin on CV outcomes during and after incident MI in the 
Trial Evaluating Cardiovascular Outcomes with Sitagliptin (TECOS).
Methods: TECOS randomized 14,671 participants with type 2 diabetes and atherosclerotic cardiovascular disease 
(ASCVD) to sitagliptin or placebo, in addition to usual care. For those who had a within-trial MI, we analyzed case fatal-
ity, and for those with a nonfatal MI, we examined a composite cardiovascular (CV) outcome (CV death or hospitaliza-
tion for heart failure [hHF]) by treatment group, using Cox proportional hazards models left-censored at the time of 
the first within-trial MI, without and with adjustment for potential confounders, in intention-to-treat analyses.
Results: During TECOS, 616 participants had ≥ 1 MI (sitagliptin group 300, placebo group 316, HR 0.95, 95% CI 0.81–
1.11, P = 0.49), of which 25 were fatal [11 and 14, respectively]). Of the 591 patients with a nonfatal MI, 87 (15%) died 
subsequently, with 66 (11%) being CV deaths, and 57 (10%) experiencing hHF. The composite outcome occurred in 
58 (20.1%; 13.9 per 100 person-years) sitagliptin group participants and 50 (16.6%; 11.7 per 100 person-years) placebo 
group participants (HR 1.21, 95% CI 0.83–1.77, P = 0.32, adjusted HR 1.23, 95% CI 0.83–1.82, P = 0.31). On-treatment 
sensitivity analyses also showed no significant between-group differences in post-MI outcomes.
Conclusions: In patients with type 2 diabetes and ASCVD experiencing an MI, sitagliptin did not reduce subsequent 
risk of CV death or hHF, contrary to expectations derived from preclinical animal models.
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Background
Dipeptidyl peptidase-4 inhibitors (DPP-4is) lower plasma 
glucose and glycated hemoglobin in people with type 2 
diabetes by inhibiting degradation of endogenous gluca-
gon-like peptide-1 (GLP-1) [1]. They have a low risk for 
hypoglycemia and are weight neutral [2]. Although two 
GLP-1 receptor agonists, once-daily liraglutide [3] and 
once-weekly semaglutide [4], have been shown to reduce 
cardiovascular (CV) events in patients with type 2 diabe-
tes at high CV risk, four CV outcome trials that evaluated 
the once-daily DPP-4i agents saxagliptin [5], alogliptin 
[6], sitagliptin [7, 8], and linagliptin [9, 10] versus placebo 
showed no impact on CV death, myocardial infarction 
(MI), or stroke outcomes.
GLP-1 receptors are expressed on cells in CV tissues 
[11], and multiple CV effects of GLP-1 receptor agonism 
have been demonstrated with administration of native 
GLP-1, with administration of GLP-1 receptor agonists, 
and with DPP-4i treatment in preclinical studies [11–14]. 
Among these well-documented effects is a substantial 
(30–50%) reduction in the extent of myocardial necrosis 
after experimentally induced MI in rodents pretreated 
with native GLP-1 [15, 16] or with a GLP-1 receptor 
agonist [17, 18]. Similar experimental approaches with 
a DPP-4i in mice [19], rats [20], pigs [21], and dogs [22] 
produced largely similar results. Regarding potential 
mechanisms, sitagliptin seems to improve tolerance to 
ischemia as demonstrated by an improved regional con-
tractility in ischemic segments of the left ventricle [23, 
24]. These effects of DPP-4 inhibition may be mediated 
by protection of mitochondrial function and preventing 
cardiomyocyte apoptosis, and by interfering with oxida-
tive stress during reperfusion [20, 21]. Theoretically, a 
smaller infarct size in humans could result in lower inci-
dent case-fatality, less post-MI arrhythmogenic risk, and 
higher residual left-ventricular function with a lower 
future risk of heart failure or CV death [25, 26].
The Trial Evaluating Cardiovascular Outcomes with 
Sitagliptin (TECOS) randomized patients with type 
2 diabetes and atherosclerotic cardiovascular disease 
(ASCVD) to double-blind therapy with sitagliptin or 
placebo, in addition to usual care, aiming for glycemic 
equipoise [7, 8]. In a post hoc analysis, we evaluated the 
effects of sitagliptin on a composite outcome defined as 
CV death or hospitalization for heart failure (hHF) in 
TECOS participants who experienced a within-trial MI.
Methods
Study design
The TECOS design [8] and primary results [7] and 
heart failure outcomes [27] have been published pre-
viously. Briefly, 14,671 participants from 38 countries 
were enrolled between December 2008 and July 2012. 
Eligible participants were ≥ 50  years old (no upper age 
limit) with type 2 diabetes, ASCVD, and glycated hemo-
globin  (HbA1c) values of 6.5–8.0% (48–64  mmol/mol) 
on stable dose mono- or dual-combination therapy with 
metformin, pioglitazone, sulfonylurea or insulin (with 
or without metformin). Participants were randomized 
double-blind to sitagliptin or placebo at doses appropri-
ate for their eGFR [7, 8]. During follow-up, treatment for 
hyperglycemia and for type 2 diabetes comorbidities was 
provided by usual care providers according to their local 
guidelines with addition of any open-label glucose-low-
ering agent permitted, apart from a GLP-1 receptor ago-
nist or DPP-4i. All reported events of death, MI, stroke, 
and hospitalization for unstable angina or heart failure 
were adjudicated by an independent committee masked 
to randomized treatment assignment. Adjudicated event 
definitions have been published previously [7, 8].
Objectives
The analyses presented here examine only those par-
ticipants who experienced an MI during the trial. We 
evaluated potential differences between the randomized 
groups in case-fatality and for those with a non-fatal MI 
the time to a composite outcome defined as CV death 
or hHF. Secondary outcomes were post-MI time to CV 
death, hHF, and all-cause death. We also examined hHF 
in patients not known to have heart failure at baseline, 
and an extended composite outcome defined as CV 
death, hHF, a further MI, stroke, or new-onset atrial 
fibrillation.
Statistical analysis
Baseline characteristics for continuous variables were 
summarized as median and interquartile range (IQR), 
and categorical variables as count (percentage).
Primary analyses were performed on the intention-to-
treat population in the subset who experienced an MI 
during the trial. Secondary on-treatment sensitivity anal-
yses were performed with participants classified as “DPP-
4i treated” if they were taking double-blind sitagliptin 
study medication or if they were taking an open-label 
DPP-4i. Similarly, they were classified as “not DPP-4i 
treated” if they were taking double-blind placebo study 
medication or had discontinued double-blind sitaglip-
tin study medication and were not taking an open-label 
DPP-4i.
The two treatment groups were compared using Cox 
proportional hazards models, without and with adjust-
ment for potential confounders. Adjustment factors 
applied were those previously identified in the large Nat-
eglinide and Valsartan in Impaired Glucose Tolerance 
Outcomes Research (NAVIGATOR) clinical trial [28, 29]. 
The assumptions of linearity and proportional hazards 
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Table 1 Baseline characteristics of  TECOS participants who did not  have a  within-trial nonfatal myocardial infarction 
(MI), and for those participants with a nonfatal MI, split by sitagliptin or placebo treatment
Characteristic Patients without a nonfatal MI 
during the trial randomized to sitagliptin 
or placebo
N = 14,055
Patients with a nonfatal MI 
during the trial
P-value*
Sitagliptin
N = 289
Placebo
N = 302
Age at randomization (years)a 65.0 (60.0, 71.0) 67.0 (62.0, 74.0) 66.0 (60.0, 72.0) 0.1414
Female 4161 (29.6%) 56 (19.4%) 75 (24.8%) 0.1103
Hispanic or Latino 1754 (12.5%) 17 (5.9%) 22 (7.3%) 0.4924
Race 0.4603
 White 9472 (67.4%) 235 (81.3%) 234 (77.5%)
 Black 422 (3.0%) 10 (3.5%) 14 (4.6%)
 Asian 3184 (22.7%) 38 (13.1%) 42 (13.9%)
 Other 977 (7.0%) 6 (2.1%) 12 (4.0%)
Region 0.5023
 Latin America 1445 (10.3%) 10 (3.5%) 11 (3.6%)
 Asia Pacific and other 4377 (31.1%) 98 (33.9%) 84 (27.8%)
 Western Europe 1977 (14.1%) 48 (16.6%) 50 (16.6%)
 Eastern Europe 3822 (27.2%) 63 (21.8%) 68 (22.5%)
 North America 2434 (17.3%) 70 (24.2%) 89 (29.5%)
Durationb of type 2 diabetes (years) 10.0 (5.0, 16.0) 11.0 (6.0, 18.0) 11.0 (6.0, 16.0) 0.3233
Diabetes therapy at baseline (alone or in combination)
 Sulfonylurea 6394 (45.5%) 110 (38.1%) 125 (41.4%) 0.4085
 Metformin 11,501 (81.8%) 212 (73.4%) 235 (77.8%) 0.2069
 Thiazolidinedione 376 (2.7%) 9 (3.1%) 9 (3.0%) 0.9245
 Insulin 3208 (22.8%) 98 (33.9%) 98 (32.5%) 0.7063
Preexisting vascular disease 13,975 (99.4%) 288 (99.7%) 302 (100.0%) 0.4890
Coronary artery disease 10,312 (73.4%) 261 (90.3%) 269 (89.1%) 0.6208
Cerebrovascular disease 3445 (24.5%) 72 (24.9%) 65 (21.5%) 0.3289
Peripheral arterial disease 2348 (16.7%) 40 (13.8%) 42 (13.9%) 0.9814
Prior MI 5899 (42.0%) 171 (59.2%) 170 (56.3%) 0.4790
Prior congestive heart failure 2511 (17.9%) 62 (21.5%) 61 (20.2%) 0.7072
Previous atrial fibrillation/flutter 1086 (7.7%) 32 (11.1%) 45 (14.9%) 0.1670
NYHA classification 0.3241
 1 510 (20.3%) 16 (25.8%) 8 (13.1%)
 2 1256 (50.0%) 24 (38.7%) 30 (49.2%)
 3 339 (13.5%) 6 (9.7%) 10 (16.4%)
 4 11 (0.4%) 1 (1.6%) 1 (1.6%)
 Not available 395 (15.7%) 15 (24.2%) 12 (19.7%)
Qualifying HbA1c (mmol/mol) 55.2 (50.8, 60.7) 56.1 (51.0, 61.7) 55.2 (51.9, 59.6) 0.3239
Qualifying HbA1c (%) 7.2 (6.8, 7.7) 7.3 (6.8, 7.8) 7.2 (6.9, 7.6) 0.3239
eGFR (mL/min/1.73 m2) 73.0 (60.0, 88.0) 68.5 (55.0, 84.0) 69.0 (56.0, 88.0) 0.2918
Urine albumin creatinine ratio (g/mol creatinine) 10.6 (3.5, 35.0) 12.2 (5.3, 52.7) 13.8 (5.3, 43.9) 0.9026
Heart rate (bpm) 72.0 (65.0, 79.0) 70.0 (62.0, 78.0) 71.0 (62.0, 80.0) 0.0595
Body mass index (kg/m2) 29.5 (26.3, 33.2) 29.8 (26.6, 33.5) 30.4 (27.2, 34.3) 0.1480
Weight (kg) 83.0 (71.0, 96.0) 85.0 (75.0, 98.0) 88.5 (75.0, 100.0) 0.1517
Height (cm) 168.0 (160.0, 174.2) 169.4 (163.2, 175.3) 170.0 (162.6, 176.0) 0.5036
Cigarette smoking status 0.9049
 Current 1589 (11.3%) 44 (15.2%) 43 (14.2%)
 Former 5575 (39.7%) 129 (44.6%) 133 (44.0%)
 Never 6891 (49.0%) 116 (40.1%) 126 (41.7%)
Systolic blood pressure (mmHg) 133.0 (124.0, 145.0) 136.0 (124.0, 146.0) 135.0 (124.0, 148.0) 0.9803
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had been previously evaluated for the set of confounders 
considered and appropriate adjustments applied when 
violations were noted. The list of covariates is provided 
in Additional file  1: Table  S1. The proportional hazards 
assumption was tested for the treatment factor in these 
new models, and time-varying models would have been 
applied had violations been noted. Follow-up began (day 
0) at the date of the first within-trial MI and continued 
until the date of the first occurrence of each type of end-
point considered here or the date of last contact when no 
event occurred. The analyses were performed twice in 
consideration of fatal MIs. In one case (primary analy-
ses), only patients with nonfatal MIs were considered; in 
the second, the fatal MIs were in the cohort and included 
as endpoints.
All analyses were performed using SAS version 9.4 
(SAS Institute, Cary, NC).
Results
Participant characteristics
Baseline characteristics of all participants at entry to 
TECOS are listed in Table  1 according to whether or 
not they had experienced an MI. Those with, compared 
without, an MI were more likely to be male (77.9% vs. 
70.4%, P < 0.0001), to have prior coronary artery disease 
(89.4% vs. 73.4%, P < 0.0001), prior MI (57.8% vs. 42.0%, 
P < 0.0001) or prior hHF (21.4% vs. 17.9%, P = 0.024); 
and to be treated less commonly with metformin (75.5% 
vs. 81.8%, P < 0.0001) and more commonly with insulin 
(33.5% vs. 22.8%, P < 0.0001).
Fatal and nonfatal MI
A total of 616 (4.2%) of the 14,671 TECOS participants 
had a within-trial fatal or nonfatal MI (300 [49%] rand-
omized to sitagliptin and 316 [51%] to placebo), with no 
significant difference in the time to first event by rand-
omized therapy (HR 0.95, 95% CI 0.81–1.11, P = 0.49) 
as reported previously [7]. Outcome information was 
missing for one participant for hHF and for two other 
participants for atrial fibrillation and stroke, limiting the 
number of participants who could be analyzed for these 
outcomes to 615 and 614, respectively. Twenty-five of 
these first MI events were fatal, 11 in the sitagliptin group 
and 14 in the placebo group, leaving 289 and 302 partici-
pants respectively with nonfatal MIs. Of the 591 partici-
pants who had a within-trial nonfatal MI, 87 (15%) died 
subsequently (66 [11%] classified as CV death), 57 (10%) 
experienced hHF, 109 (18%) had a second MI, 20 (3%) 
had a stroke, and 37 (6%) had incident atrial fibrillation.
CV events after nonfatal MI
The composite outcome of CV death or hHF following a 
nonfatal MI occurred in 58 of 289 sitagliptin group par-
ticipants (20.1%; 13.9 events per 100 person-years) and 
in 50 of 302 placebo group participants (16.6%; 11.7 per 
100 person-years), with no significant difference between 
groups (HR 1.21, 95% CI 0.83–1.77, P = 0.32; adjusted HR 
1.23, 95% CI 0.83–1.82, P = 0.31) (Fig.  1a and Table  2). 
Similar results were seen for the individual outcomes of 
CV death, hHF, incident heart failure, recurrent MI, and 
all-cause death, and for the extended composite (CV 
death, hHF, incident heart failure, recurrent MI, stroke, 
Data shown are median (interquartile range) or N (%)
ACE angiotensin-converting enzyme, eGFR estimated glomerular filtration rate, HbA1c glycated hemoglobin, LDL-C low-density lipoprotein cholesterol, NYHA New 
York Heart Association, TECOS Trial Evaluating Cardiovascular Outcomes with Sitagliptin
*P-value is for placebo vs sitagliptin in patients with a nonfatal MI
a Age is missing among patients enrolled in Lithuania because the entire birth date including year was not available
b Duration = (year of randomization − year of diagnosis) + 1
Table 1 (continued)
Characteristic Patients without a nonfatal MI 
during the trial randomized to sitagliptin 
or placebo
N = 14,055
Patients with a nonfatal MI 
during the trial
P-value*
Sitagliptin
N = 289
Placebo
N = 302
Diastolic blood pressure (mmHg) 79.0 (70.0, 84.0) 77.0 (68.0, 82.0) 76.0 (68.0, 85.0) 0.3050
LDL-C 84.0 (65.0, 109.0) 81.0 (63.0, 99.6) 82.1 (65.6, 108.1) 0.4128
Medications taken at time of randomization
 Statins 11,213 (79.8%) 238 (82.4%) 248 (82.1%) 0.9408
 ACE inhibitors or angiotensin receptor blockers 11,040 (78.5%) 238 (82.4%) 255 (84.4%) 0.4959
 Diuretics 5727 (40.7%) 127 (43.9%) 150 (49.7%) 0.1633
 Calcium channel blockers 4730 (33.7%) 104 (36.0%) 118 (39.1%) 0.4386
 Beta blockers 8876 (63.2%) 210 (72.7%) 221 (73.2%) 0.8881
 Aspirin 11,027 (78.5%) 244 (84.4%) 235 (77.8%) 0.0403
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Fig. 1 Unadjusted event curves by randomized assignment to sitagliptin or placebo (Kaplan–Meier plots) for the composite outcome of 
cardiovascular (CV) death or heart failure hospitalization (hHF) (a) and for CV death (b), both occurring after the first within-trial nonfatal myocardial 
infarction (MI) (defining day 0 on the x-axis). Intention-to-treat analysis
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or incident atrial fibrillation), with no significant differ-
ences also seen after adjustment for potential confound-
ers (Table  2). Results were also similar when fatal MI 
was included in the cohort of interest (Additional file 1: 
Table S2, Figure S1).
On-treatment sensitivity analyses
At the time of the first nonfatal MI, 249 (42%) par-
ticipants were taking a DPP-4i and 341 (58%) were not. 
There was no significant difference in the composite out-
come of CV death or hHF for those treated or not treated 
with a DPP-4i (Fig.  2a and Table  3) for either unad-
justed analyses (HR 0.91, 95% CI 0.62–1.34, P = 0.63) or 
adjusted analyses (HR 0.95, 95% CI 0.64–1.43, P = 0.82). 
All results were consistent with those for the intention-
to-treat analyses, although CV deaths were numerically 
less in those treated with a DPP4i (HR 0.75). Results were 
also consistent when first fatal MI was included in the 
analysis (Additional file 1: Table S3, Figure S2).
Discussion
Although preclinical data provided theoretical support 
[19–22], these post hoc TECOS analyses found no evi-
dence that treatment with sitagliptin, compared with pla-
cebo, given prior to a first within-trial nonfatal MI had 
any impact on subsequent CV outcomes. Similar results 
were obtained when previous use of any DPP-4i was 
examined, and in sensitivity analyses that included fatal 
as well as nonfatal MIs.
Possible explanations for the discordance between 
human and animal observations include the follow-
ing: (1) all TECOS participants had established ASCVD 
versus the lack of disease in experimental animals; (2) 
our study had only modest statistical power with just 123 
composite outcome events analyzed; (3) experimentally 
induced MI is typically the consequence of total occlu-
sion of a large coronary vessel, leading to a rather large 
area of myocardial necrosis, associated with adverse 
clinical consequences and significant mortality in the 
animal models—in contrast, spontaneous acute MI in 
humans is more variable in terms of the size of the rel-
evant coronary vessel and the corresponding size of the 
subtended myocardium, whether complete occlusion of 
the coronary occurs, and marked variability in the tim-
ing from MI onset to clinical presentation, all of which 
translates into highly variable sizes of the area at risk, i.e. 
receiving blood supply from the infarct-related vessel, 
and of the necrotic area [25, 26]; (4) the doses of sitag-
liptin used in the animal studies are roughly twofold or 
more higher [19–22]; and (5) not all TECOS participants 
may have been adherent with respect to their study medi-
cation, and the GLP-1 receptor agonism augmented by 
DPP-4is does not have the same CV consequences in 
humans that has been demonstrated in animal studies 
[15–22]. Our results, however, are supported by negative 
results reported from a similar analysis of the Liraglutide 
Effect and Action in Diabetes: Evaluation of Cardiovas-
cular Outcome Results (LEADER) trial examining effects 
of liraglutide versus placebo pretreatment on CV events 
following MI occurring during the trial [30].
Controversy persists regarding the effects of DPP-4is 
on heart failure risk, originating from the observation 
of an increased risk of hHF with saxagliptin in the Saxa-
gliptin Assessment of Vascular Outcomes Recorded in 
Table 2 Cardiovascular outcomes occurring after a first within-trial non-fatal myocardial infarction in those randomized 
previously to sitagliptin or placebo treatment (intention-to-treat analysis)
Sitagliptin
n = 289
Placebo
n = 302
Unadjusted 
hazard ratio 
(95% CI)
P-value Adjusted 
hazard ratio 
(95% CI)
P-value
No. (%) Events 
per 100 
patient-years
No. (%) Events 
per 100 
patient-years
Cardiovascular death or hospitali-
zation for heart failure
58 (20.1) 13.9 50 (16.6) 11.7 1.21 (0.83–1.77) 0.32 1.23 (0.83–1.82) 0.31
Cardiovascular death 34 (11.8) 7.6 32 (10.6) 7.1 1.11 (0.68–1.81) 0.67 1.12 (0.67–1.86) 0.67
Hospitalization for heart failure 31 (10.7) 7.5 26 (8.6) 6.1 1.26 (0.75–2.12) 0.39 1.40 (0.80–2.42) 0.23
New onset heart failure 19 (6.6) 4.3 17 (5.6) 3.8 1.25 (0.64–2.44) 0.51 1.49 (0.72–3.09) 0.28
Cardiovascular death, hospital 
admission for heart failure, new 
heart failure, acute myocardial 
infarction, stroke or new-onset 
atrial fibrillation
108 (37.4) 33.0 100 (33.1) 28.4 1.16 (0.89–1.53) 0.27 1.21 (0.91–1.60) 0.20
Further acute myocardial infarc-
tion
54 (18.7) 7.4 55 (18.2) 7.1 1.01 (0.69–1.48) 0.95 0.99 (0.67–1.46) 0.95
All-cause death 50 (17.3) 11.0 37 (12.3) 8.1 1.40 (0.92–2.15) 0.12 1.41 (0.90–2.21) 0.13
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Fig. 2 Unadjusted event curves by dipeptidyl peptidase-4 inhibitor (DPP-4i) treatment received versus no treatment (Kaplan–Meier plots) for 
the composite outcome of cardiovascular (CV) death or heart failure hospitalization (hHF) (a) and for CV death (b), both occurring after the first 
within-trial nonfatal myocardial infarction (MI) (defining day 0 on the x-axis). On-treatment sensitivity analysis
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Patients with Diabetes Mellitus-Thrombolysis in Myo-
cardial Infarction 53 (SAVOR-TIMI) 53 trial [31] with a 
similar non-significant trend in the Examination of Car-
diovascular Outcomes with Alogliptin versus Standard 
of Care (EXAMINE) trial with alogliptin [32], but no 
hHF signal observed with sitagliptin [27] or linagliptin 
[33]. On the other hand, results from observational stud-
ies have yielded counter-observations, reporting lower 
hHF risk associated with DPP-4i use compared with 
GLP-1 receptor agonists, with no significant difference in 
patients with a history of heart failure [34], and no differ-
ence in the risk of hHF when DPP-4i use was compared 
with sulfonylurea [35]. If DPP-4i treatment increases 
heart failure risk, the mechanism remains elusive. By 
echocardiographic criteria, a trend toward worsening 
diastolic ventricular function was slowed with sitagliptin 
treatment [36]. As a potential reason for a heterogene-
ity in effects between different DPP-4is, a suppression of 
renal sodium-hydrogen exchanger 3 activity with agents 
that are excreted in the urine (sitagliptin, alogliptin and 
linagliptin) has been proposed to protect from DPP-
4i–induced heart failure [37]. In the present analysis, 
in accord with prior results of no heart failure effects of 
sitagliptin in the overall TECOS cohort, no association 
between sitagliptin and heart failure events was observed 
post-MI [7, 8, 27]. Thus, sitagliptin seems to be safe in 
patients during and after acute MI. Whether this applies 
to other DPP-4is needs to be studied in dedicated analy-
ses from the respective CV outcomes trials [5, 6, 10]. 
Along these lines, a meta-analysis of other CV outcomes 
trials with DPP-4is (e.g. SAVOR TIMI-53 [5], EXAM-
INE [6], CArdiovascular safety and Renal Microvascular 
outcomE study with LINAgliptin [CARMELINA] [9, 10], 
and CARdiovascular Outcome Trial of LINAgliptin Ver-
sus Glimepiride in Type 2 Diabetes [CAROLINA] [38]) 
could provide further clarification.
Limitations of the present analyses include the non-
randomized selection of the subset with MI for analysis 
[7, 8]. In addition, incomplete adherence to randomized 
treatment that could have occurred selectively post-MI 
could further confound comparative analyses. These 
analyses had limited power given the relatively few 
patients with MI with subsequent outcomes of interest. 
However, this data set is larger than most available with 
an ability to explore such associations.
Conclusions
In summary, these post hoc analyses of data from TECOS 
participants who had type 2 diabetes and ASCVD do not 
support the preclinically derived hypothesis that DPP-4i 
treatment prior to an MI can reduce the subsequent risk 
of CV death or hHF.
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Additional file 1: Table S1. Factors included in adjustment models for 
each clinical endpoint. Table S2. Cardiovascular outcomes occurring 
after a first within-trial fatal or nonfatal myocardial infarction in those 
randomized previously to sitagliptin or placebo treatment (intention-to-
treat analysis). Table S3. Cardiovascular outcomes occurring after a first 
within-trial fatal or nonfatal myocardial infarction in those pretreated or 
not pretreated with a DPP-4i (on-treatment sensitivity analysis). Figure 
S1. Unadjusted event curves by randomized assignment to sitagliptin or 
Table 3 Cardiovascular outcomes occurring after  a  first within-trial nonfatal myocardial infarction in  those pretreated 
or not pretreated with a dipeptidyl peptidase-4 inhibitor (DPP-4i) (on-treatment sensitivity analysis)
DPP-4i treated
n = 249
Not DPP-4i treated
n = 341
Unadjusted 
hazard ratio 
(95% CI)
P-value Adjusted 
hazard ratio 
(95% CI)
P-value
No. (%) Events 
per 100 
patient-years
No. (%) Events 
per 100 
patient-years
Cardiovascular death or hospitali-
zation for heart failure
45 (18.1) 11.9 62 (18.2) 13.3 0.91 (0.62–1.34) 0.63 0.95 (0.64–1.43) 0.82
Cardiovascular death 25 (10.0) 6.2 40 (11.7) 8.1 0.78 (0.47–1.29) 0.34 0.75 (0.44–1.26) 0.27
Hospitalization for heart failure 27 (10.8) 7.2 30 (8.8) 6.4 1.15 (0.68–1.94) 0.60 1.34 (0.77–2.33) 0.31
New onset heart failure 16 (6.4) 4.0 20 (5.9) 4.1 1.05 (0.54–2.05) 0.88 1.34 (0.64–2.79) 0.44
Cardiovascular death, hospital 
admission for heart failure, new 
heart failure, acute myocardial 
infarction, stroke or new-onset 
atrial fibrillation
87 (34.9) 28.8 120 (35.2) 31.8 0.92 (0.70–1.22) 0.56 0.95 (0.71–1.27) 0.72
Further acute myocardial infarction 46 (18.5) 7.2 63 (18.5) 7.3 0.97 (0.66–1.42) 0.89 0.99 (0.67–1.46) 0.95
All-cause death 37 (14.9) 8.9 49 (14.4) 9.9 0.94 (0.61–1.44) 0.77 0.91 (0.58–1.43) 0.68
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placebo (Kaplan–Meier plots) for the composite outcome of cardiovascu-
lar death or heart failure hospitalization (A) and for cardiovascular death 
(B), both occurring after the first within-trial myocardial infarction during 
the TECOS trial (defining day 0 on the x-axis). Intention-to-treat analysis. 
Figure S2. Unadjusted event curves by treatment received, DPP-4i versus 
no DPP-4i, Kaplan-Meier plots for the composite outcome of cardiovascu-
lar death or heart failure hospitalization (A), and for cardiovascular death 
(B), both occurring after the first nonfatal within-trial myocardial infarction 
(defining day 0 on the x-axis). On-treatment sensitivity analysis.
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